Al-Madina Pharmaceuticals PLC began its journey in 2006 as part of the Al-Madina Group, with a commitment to producing quality medicines at affordable prices. The company started commercial operations in October 2007, initially focusing on veterinary medicines before expanding into human pharmaceuticals in 2019. With modern manufacturing facilities and a strong focus on quality control, it has steadily developed its presence in Bangladesh’s pharmaceutical industry. The company employs more than 700 people and follows Good Manufacturing Practices (GMP) to maintain product quality and safety. Today, Al-Madina offers medicines across numerous therapeutic categories, including antibiotics, antifungals, gastrointestinal treatments, vitamins, and nutritional supplements. Its veterinary portfolio also includes poultry vaccines and aquaculture products. The company operates 12 distribution centres nationwide, supported by its own logistics network. In 2022, it became a public limited company and was listed on the stock exchanges in Dhaka and Chittagong in May 2023.